Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 24484977)

1.

Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Howell LL, Negus SS.

Adv Pharmacol. 2014;69:129-76. doi: 10.1016/B978-0-12-420118-7.00004-4. Review.

2.

Therapeutic potential of monoamine transporter substrates.

Rothman RB, Baumann MH.

Curr Top Med Chem. 2006;6(17):1845-59.

PMID:
17017961
3.

Monoamine transporters and psychostimulant addiction.

Howell LL, Kimmel HL.

Biochem Pharmacol. 2008 Jan 1;75(1):196-217. Epub 2007 Aug 7. Review.

PMID:
17825265
5.

Dopamine/serotonin releasers as medications for stimulant addictions.

Rothman RB, Blough BE, Baumann MH.

Prog Brain Res. 2008;172:385-406. doi: 10.1016/S0079-6123(08)00919-9. Review.

PMID:
18772043
6.

Monoamine transporters and psychostimulant drugs.

Rothman RB, Baumann MH.

Eur J Pharmacol. 2003 Oct 31;479(1-3):23-40. Review.

PMID:
14612135
7.

Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B.

Pharmacol Biochem Behav. 2010 Jun;95(4):449-56. doi: 10.1016/j.pbb.2010.03.006. Epub 2010 Mar 25.

9.

Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

Rothman RB, Blough BE, Baumann MH.

Exp Clin Psychopharmacol. 2008 Dec;16(6):458-74. doi: 10.1037/a0014103. Review.

10.
11.
12.

Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging.

Lindsey KP, Wilcox KM, Votaw JR, Goodman MM, Plisson C, Carroll FI, Rice KC, Howell LL.

J Pharmacol Exp Ther. 2004 Jun;309(3):959-69. Epub 2004 Feb 24.

13.

Agents in development for the management of cocaine abuse.

Gorelick DA, Gardner EL, Xi ZX.

Drugs. 2004;64(14):1547-73. Review.

PMID:
15233592
14.

Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs.

Rothman RB, Baumann MH.

Ann N Y Acad Sci. 2006 Aug;1074:245-60. Review.

PMID:
17105921
15.

Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys.

Banks ML, Bauer CT, Blough BE, Rothman RB, Partilla JS, Baumann MH, Negus SS.

Exp Clin Psychopharmacol. 2014 Jun;22(3):274-84. doi: 10.1037/a0036595. Epub 2014 May 5.

16.

Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies.

Herin DV, Rush CR, Grabowski J.

Ann N Y Acad Sci. 2010 Feb;1187:76-100. doi: 10.1111/j.1749-6632.2009.05145.x. Review.

PMID:
20201847
17.

Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.

Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH.

J Pharmacol Exp Ther. 2005 Jun;313(3):1361-9. Epub 2005 Mar 10.

18.

The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP.

Adv Pharmacol. 2014;69:71-106. doi: 10.1016/B978-0-12-420118-7.00002-0. Review.

19.
20.

Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.

Rothman RB, Blough BE, Baumann MH.

AAPS J. 2007 Jan 5;9(1):E1-10. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk